海洋双吲哚化合物联合阿糖胞苷（Ara-C）在制备治疗急性髓系白血病（AML）药物中的应用

By combining the marine bisindole compound FGFC1 with cytarabine, tumor cell signaling pathways were inhibited, solving the side effects problem of high-dose cytarabine treatment for acute myeloid leukemia and achieving a safer and more effective treatment.

CN116687920BActive Publication Date: 2026-07-17SHANGHAI OCEAN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SHANGHAI OCEAN UNIV
Filing Date
2023-07-24
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

In existing technologies, high-dose antitumor drugs such as cytarabine have serious side effects when treating acute myeloid leukemia, and patients often find them difficult to tolerate. Therefore, more effective treatment measures are being sought to overcome this problem.

Method used

The combined use of marine bisindole compound FGFC1 and cytarabine significantly inhibited tumor cell activity, reduced toxic side effects, and improved therapeutic efficacy by suppressing the NF-κB and EGFR/PI3K/Akt signaling pathways in tumor cells.

Benefits of technology

Achieving efficacy comparable to monotherapy at lower doses, reducing drug resistance in tumor cells, minimizing toxic side effects, and expanding application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116687920B_ABST
    Figure CN116687920B_ABST
Patent Text Reader

Abstract

本发明属于海洋抗癌药物应用技术领域，具体涉及海洋双吲哚化合物联合抗肿瘤药物在抗肿瘤治疗中的应用，尤其涉及海洋双吲哚化合物FGFC1联合阿糖胞苷(Ara‑C)在制备治疗急性髓系白血病(AML)药物中的应用。海洋双吲哚化合物FGFC1通过抑制肿瘤细胞中NF‑κB信号通路显示抗癌活性，在AML的治疗中，与阿糖胞苷(Ara‑C)药物联合施用，可以显著抑制急性髓系白血病(AML)细胞系中EGFR / PI3K / Akt通路的激活，对抑制肿瘤细胞活性起到协同增效作用。
Need to check novelty before this filing date? Find Prior Art